
May 10, 2022
Fusion Pharmaceuticals Announces First Quarter 2022 Financial Results And Clinical Program Updates
Phase 1 data for FPI-1434 anticipated to be reported in the second half of 2022
Company continues to build a diversified pipeline of TATs and advance manufacturing and actinium...
Read more
Read more

May 10, 2022
Targovax and Oslo University Hospital announce collaboration to test TG mutant RAS vaccination in multiple myeloma
Targovax has entered into an agreement with Oslo University Hospital (OUS) to test TG01 in a phase 1/2 trial in 20 patients with RAS mutant multiple myelomaThe trial will be spons...
Read more
Read more

May 6, 2022
Nordic Nanovector ASA: Invitation to First Quarter 2022 Results Presentation and Webcast
Oslo, Norway, 6 May 2022
Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the first quarter 2022 on Friday, 13 May 2022.
A presentation by No...
Read more
Read more

May 5, 2022
Interim report January – March 2022
Gothenburg, May 5, 2022 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2022.
Important events during the first quarter
In February, an ...
Read more
Read more

May 4, 2022
Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022
Conference call and webcast at 8:30am ET
CHICAGO--(BUSINESS WIRE)--May 4, 2022-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company devel...
Read more
Read more

May 4, 2022
BONESUPPORT Holding AB (publ) – Publishes Q1 2022 interim report
Published: 2022-05-04
BONESUPPORT Holding AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first q...
Read more
Read more

May 4, 2022
Oncopeptides publishes Q1 report 2022
STOCKHOLM — May 4, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematologi...
Read more
Read more

May 3, 2022
Pulmonx Reports First Quarter 2022 Financial Results
REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lu...
Read more
Read more

May 3, 2022
Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small moleculesAdcendo building a world class team of experienced biotec...
Read more
Read more

May 3, 2022
Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin® in Combination with the PARP-inhibitor Olaparib
Second publication reports on CD37-targeting imaging approach to select NHL patients who might respond best to Humalutin® treatment
Oslo, Norway, 3 May 2022
Nordic Na...
Read more
Read more